Wedbush Maintains Outperform on Builders FirstSource, Raises Price Target to $95

Wedbush analyst Jay McCanless maintains Builders FirstSource (NYSE:BLDR) with a Outperform and raises the price target from $80 to $95.

byBenzinga Newsdesk

February 27, 2023

1 minute read

Wedbush analyst Jay McCanless maintains Builders FirstSource (NYSE:BLDR) with a Outperform and raises the price target from $80 to $95.

Analyst Ratings

Analyst Ratings for Intercept Pharmaceuticals

By Benzinga Insights

Today, 3:05 AM

Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter: Bullish Somewhat Bullish Indifferent…

ICPT

Aquestive Therapeutics Reports Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

By Michael Horton

Today, 3:05 AM

AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes Study continues to

AQST

Goldman Sachs Maintains Buy on Lincoln National, Lowers Price Target to $40

By Benzinga Newsdesk

Today, 3:05 AM

Goldman Sachs analyst Alex Scott maintains Lincoln National (NYSE:LNC) with a Buy and lowers the price target from $46 to $40.

LNC

Events
News

Neoleukin Therapeutics Reports Will Present At Canaccord’s Horizons In Oncology Conference Thursday, Apr. 14, 2022 At 12 p.m. EDT

By Benzinga Newsdesk

Today, 3:05 AM

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that

NLTX

Wedbush Maintains Outperform on Builders FirstSource, Raises Price Target to $95

Related Posts

Analyst Ratings for Intercept Pharmaceuticals

Aquestive Therapeutics Reports Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

Goldman Sachs Maintains Buy on Lincoln National, Lowers Price Target to $40

Neoleukin Therapeutics Reports Will Present At Canaccord’s Horizons In Oncology Conference Thursday, Apr. 14, 2022 At 12 p.m. EDT